Vaccines Against Malarial Diseases


The invention offered for licensing is in the field of use of vaccines for malaria. The invention provides gene sequences encoding an erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification of the encoded protein in other hosts. Administration of the synthetic gene sequences, or the encoded protein, as an immunization agent is useful for induction of immunity against malaria, treatment of malaria, or both. The approach presented in this invention, i.e. vaccine that may block the binding of the malaria parasite and subsequent erythrocyte invasion, may work independently or in combination with other vaccines which are based on different mechanisms.

Potential Commercial Applications: Competitive Advantages:
Vaccine compositions against malaria in the form of DNA vaccines or as protein immunogens. Due to the complex nature of the malaria parasite, multiple approaches have been attempted to develop malaria vaccines. In particular, due to the diversity attributed to the different life cycle stages of the parasite, there are several sites that can be used as vaccine targets. The approach offered in the present invention, i.e. blockage of the binding to blood erythrocyte, may work independently or in combination with other vaccines based on different mechanisms to create an effective vaccine against malaria.


Development Stage:
Proof of concept demonstrated.

Inventors:

David Narum


Intellectual Property:
U.S. Pat: 7,078,507 issued 2006-07-18
US Application No. 60/345,051
PCT Application No. PCT/US02/036368

Publications:
H Liang and BK Sim. Conservation of structure and function of the erythrocyte-binding domain of Plasmodium falciparum EBA-175. Mol Biochem Parasitol. 1997 Feb;84(2):241-245. PubMed: 11705894
DL Narum et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun. 2001 Dec;69(12):7250-7253. PubMed: 11814568
DL Narum et al. A novel Plasmodium falciparum erythrocyte binding protein-2 (EBP2/BAEBL) involved in erythrocyte receptor binding. Mol Biochem Parasitol. 2002 Feb;119(2):159-168.

Collaboration Opportunity:

The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the erythrocyte binding protein as a malaria vaccine. Please contact Dana Hsu at 301-496-2644 for more information.


Licensing Contact:
David (Po-Lung) Yang, Ph.D.
Email: polung.yang@nih.gov
Phone: 301-496-2644

OTT Reference No: E-052-2004-0
Updated: Feb 28, 2011